Crohn's Disease Market: Current Analysis and Forecast (2022-2028)

Crohn's Disease is a type of irritable bowel disease (IBD). It causes inflammation in the intestine leading to acute abdominal pain, and fatigue followed by diarrhoea and weight loss. Inflammation due to Crohn's disease can be in different parts of the intestine most commonly the small intestine. This inflammation may spread to a deeper layer of bowel tissue. Crohn's disease may sometimes lead to life-threatening complications.

The growing prevalence of Crohn's disease Is driving the demand for the market and is expected to grow at a strong CAGR of 3% during the forecast period. For instance, according to the Centre for disease prevention and Control 2021 report, Crohn's disease affected nearly 7 million people worldwide. Further, as per the above-mentioned source, the prevalence of Crohn's disease has doubled over the past two decays. This factor is primarily driving the market growth.

Based on diagnostics, the market is segmented into blood tests, faecal tests, colonoscopies, flexible sigmoidoscopy, computerized tomography, magnetic resonance imaging and others. Amongst these, the colonoscopy segment is anticipated to grow with a significant CAGR in the 2021 market. This is attributed to the accuracy and efficiency of colonoscopy diagnostics. Colonoscopy allows accurate diagnosis of Crohn's disease in up to 9 out of 10 cases. Doctors use a colonoscopy to find the cause of symptoms such as rectal bleeding.

Based on treatment, the market is bifurcated into medication and surgery. Amongst these, the medication segment is anticipated to grow with a significant CAGR in the forecasted period. Crohn's disease is an autoimmune disorder, which means the body's immune system mistakenly attacks the body's healthy tissue, causing inflammation. Additionally, Crohn's disease is a chronic condition which means it may occur and re-occur at various times. Furthermore, medications such as immunosuppressants are used for the treatment of Crohn's disease. These immunosuppressant acts by suppressing the immune response and ultimately suppress the symptoms. Moreover, the treatment with medication is always the drug of choice preferred by the patient and by the doctor due to its compliance over surgeries.

For a better understanding of the market adoption of the Crohn's Disease industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, and the Rest of North America), Europe (Germany, UK, Netherlands, France, Norway, Switzerland, Denmark, Rest of Europe), Asia-Pacific (China, Japan, India, South Korea, and Rest of Asia-Pacific), Rest of World. Asia-pacific is anticipated to grow with a significant CAGR during the forecasted period. this is primarily driven by the increase in demand for drugs that can induce and maintain remission and reduce symptoms thus, improving the quality of life. The most commonly used medication for Crohn's disease includes aminosalicylic acids, corticosteroids, immunomodulators and biologics. Additionally, factors such as the development of novel drug therapy for the treatment and growing demand for personalised care are anticipated to drive market growth.

Some of the major players operating in the market include: Takeda Pharmaceutical Company Limited., Janssen Global Services, LLC, UCB S.A., Biogen, AbbVie Inc.,Genentech, Inc. ,Gilead Sciences, Inc. ,Eli Lilly and Company, Pfizer Inc., Johnson & Johnson Services, Inc.